Seagen, Inc.Equity-NMS: SGEN
Equity-NMS: SGEN
$228.74
NA
(3 Mar)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$228.74
Open
$228.74
1Y
26.17%
5Y
25.06%
EPS (TTM)
-4.01
Shares O/S
187.70M
Market cap
42.93B
Insights
SGEN has made a new 52 Wk high. 52 Wk high stocks tend to outperform in the near term.
SGEN price is below its 200 day moving average
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About Seagen, Inc.

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers.

It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. .


FAQs

Can I buy Seagen, Inc. shares in India?
How to buy Seagen, Inc. shares in India?
What is the share price of Seagen, Inc.?
What is the Market Capitalization of Seagen, Inc.?
What is the PE ratio of Seagen, Inc.?
Is Seagen, Inc. a good stock to buy?
In which sector / industry does Seagen, Inc. operate?